Jacqualyn A. Fouse - 14 Feb 2023 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role: Director
Signature: /s/ William Cook, as Attorney-in-fact for Jacqualyn Fouse
Issuer symbol: AGIO
Transactions as of: 14 Feb 2023
Net transactions value: -$105,464
Form type: 4
Filing time: 16 Feb 2023, 15:03:53 UTC
Previous filing: 04 Jan 2023
Next filing: 12 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGIO	Common stock	Options Exercise	$0	+11,333	+15%	$0.000000	86,230	14 Feb 2023	Direct
transaction	AGIO	Common stock	Tax liability	$105,464	-3,648	-4.2%	$28.91	82,582	16 Feb 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGIO	Restricted stock units	Options Exercise	$0	-11,333	-100%	$0.000000^*	0	14 Feb 2023	Common stock	11,333		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2	The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.